Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01246037
Other study ID # 2010-262
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received November 18, 2010
Last updated January 13, 2014
Start date February 2011
Est. completion date April 2014

Study information

Verified date January 2014
Source VU University Medical Center
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)
Study type Interventional

Clinical Trial Summary

The main question of this study is: 'Is selective beta-blocker treatment safe and effective in reducing sympathetic overdrive, thereby improving RV function and remodeling in patients with iPAH?'.

In addition to the determination of RVEF, the investigators will explore how beta-blocker therapy affects sympathetic overdrive, remodeling of the RV, single beat elastance, exercise capacity and mechanical efficiency.

30 iPAH patients will be randomized to either Bisoprolol- or placebo-treatment in a double-blinded fashion. A cross-over trial design will be used to increase the power of the study and to assess long-term effects of Bisoprolol-treatment and -withdrawal. The medication will be given in an escalating dose regimen (as described in the 'farmacotherapeutisch kompas', www.fk.cvz.nl) and treatment will be monitored along the guidelines of the American Heart Association.


Description:

This is a clinical study aimed to provide a proof of concept of the safety and efficacy of beta-blocker treatment in PAH-associated right ventricular failure.

The protocol of the proposed double blinded cross over design.

The reasons for not choosing an initial open phase 1 study, but to start directly with a placebo controlled study are:

1. Although the drug is considered contraindicated in the studied patient population, it is very common for PAH patients to receive beta-blocker therapy in an uncontrolled way; without reports of serious side effects until now

2. Dose titration in the study will be performed on the basis of side-effects and at this moment the investigators cannot predict the optimal dose which is both safe and efficacious. Therefore, safety assessment can only be performed in combination with the assessment of pharmaceutical effectiveness.

After obtaining informed consent, 30 idiopathic PAH patients (NYHA II-III) will be randomly assigned to either the placebo group or beta-blocker therapy. For the randomization and study blinding the investigators will use a VUMC computer based procedure in close collaboration with the VUMC pharmacy.

In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' (described below) and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.

MEASUREMENTS Time points 1, 3 and 5 (6 months periods): this includes a complete assessment of the patient

- Clinical assessment: physical examination, NYHA class, ECG, routine lab including NT-proBNP and urine tests for proteinuria.

- Imaging of right ventricular function: the primary measure of this study will be right ventricular ejection fraction measured by means of MRI. Additional MRI and echocardiographic measurements will be performed. (the complete study protocols are added as supplements).

- Right Heart Catheterization (performed under local anesthesia): Measurements of pressures in the pulmonary artery, right ventricle and right atrium, while patients are breathing room air and at end-expiration.

- Exercise capacity by means of a maximal incremental cycle testing (CardioPulmonary Exercise Test) to measure maximal work load, VO2 max, anaerobic threshold, heart rate response, oxygen pulse and ventilatory efficiency. And by means of 6 minute walking distance.

- Heart Rate Variability (HRV)

- Nuclear scanning: a comprised PET protocol will be performed to measure 11C-acetaat, oxygen-15-labeled water (H215O) and ¹¹C-HED uptake in the right ventricle. A summary of the protocol is added as a supplement.

UP-TITRATION PHASE (first 4 months; either on placebo or Bisoprolol): patients will be monitored every second week under supervision of an experienced pulmonologist, specialized in PAH, and a cardiologist, specialized in chronic heart failure during a visit to the outpatient clinic. If no contra-indications are found the dose will be increased to the next step.

The investigators will start with a dosage of 1,25 mg Bisoprolol once daily. Every two weeks dosage is increased by 1,25 mg, until maximum dosage of 10 mg once a day is reached, or as high as tolerated by the patient.

Increasing the dosage will be stopped, or if needed the dosage will be reduced, in case of:

- systolic systemic pressure < 90 mmHg

- clinical progression in heart failure

- clinically relevant bradycardia or <60b/min

- progression of complaints

- drop in 6 minute walk distance > 15% The titration procedure for the placebo will be the same as for titration of Bisoprolol. The dosage of the medication will be altered for maximal four months and after this the patients will use a stable dose for the rest of the six month period.

Every clinical visit will at least contain a clinical assessment, assessment of NYHA class, 6 minute walk distance, ECG and a Minnesota quality of life questionnaire. Every fourth week NT-proBNP, kidney- and liver functions will be assessed. In addition, the patient will be instructed to use a diary to record his/her symptoms and body weight.

STABLE PHASE: It is expected that up to 4 months are required to reach an acceptable dose of Bisoprolol. After this up-titration phase, the patient will be followed closely during the remaining part of the six month period, using a stable medication dose. The monitoring includes continuation of the diary, monthly visits to the outpatient clinic including the measurements as described in the up-titration phase and a telephone call every 4 weeks in between office visits.

CROSS OVER After six months new measurements will be done. Thereafter the medication will be tapered down in a two week period and than finally stopped. This will be done to prevent the patients for possible side effects (rebound tachycardia) of stopping their medication. The same tapering down procedure will be performed after the third set of measurements.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date April 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Idiopathic PAH patients

- Stable on PAH specific treatment defined

- No change in PAH specific treatment in the past 6 months

- No change in functional class in the past 6 months

- <10 % change in 6 minute walk distance in the past 6 months

- Functional class 2 or 3

- In sinus rhythm

Exclusion Criteria:

- History of systemic hypertension, ischaemic heart disease, valvular disease or cardiomyopathy.

- Asthma

- Use of concomitant medication other than diuretics, Acenocoumarol and PAH targeted therapy

- History of cardiac arrhythmias or the use of anti-arrhythmic drugs

- Sick sinus syndrome

- systolic hypotension < 90 mmHg

- AV-block

- Clinically relevant sinus-bradycardia

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Bisoprolol
In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.

Locations

Country Name City State
Netherlands VUmc Amsterdam

Sponsors (2)

Lead Sponsor Collaborator
VU University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectivity The primary efficacy endpoint is improvement in RV function as reflected by RVEF determined by means of cardiac MRI. 6 months No
Primary Safety Safety of Bisoprolol treatment in iPAH patients is not taken as a primary endpoint but seen as a precondition for this study and will be closely monitored. Dose titration will be guided by possible side effects. continue Yes
Secondary Is Bisoprolol treatment effective in reducing sympathetic overdrive? Herefore the investigators use a C11-Hed-, H2O15- and a C11-acetate- nuclear scan 0,6,12 months No
Secondary Is Bisoprolol effective in reversing maladaptive remodeling of the right ventricular wall, and does Bisoprolol thereby improve the diastolic properties of the right ventricle? Pressure-Volume loops will be reconstructed from the combined right heart catheterization data and MRI measurements 0,6 and 12 months No
Secondary Is Bisoprolol treatment effective in improving the perfusion and mechanical efficiency (oxygen consumption per joule) of the heart? Perfusion will be measured by using the H2O tracer. Oxygen consumption of the right ventricle will be estimated from the uptake of the acetate tracer. Right ventricular power output will be derived from the right heart catheterization data. 0,6,12 months No
Secondary Is Bisoprolol effective in improving exercise capacity? This will be measured by means of the maximal oxygen uptake which is measured by means of the incremental cardiopulmonary exercise test and six minute walking distance. Every two weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT01884051 - Hormonal, Metabolic, and Signaling Interactions in PAH
Completed NCT00626028 - Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing Phase 3
Completed NCT02790450 - Acute Effects of Benzbromaron on the Pulmonary Circulation Phase 2
Recruiting NCT05584722 - Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Completed NCT01590108 - The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects Phase 1
Recruiting NCT05493371 - Empagliflozin in Pulmonary Arterial Hypertension Phase 2
Recruiting NCT03933579 - The PAH Platform for Deep Phenotyping in Korean Subjects
Completed NCT01613287 - Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension N/A
Recruiting NCT00372346 - Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension N/A
Withdrawn NCT01645826 - Efficacy Study of Cardizem in Pulmonary Arterial Hypertension N/A
Completed NCT00641836 - Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension N/A
Not yet recruiting NCT06104228 - 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) Phase 2
Recruiting NCT02959723 - Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies N/A
Recruiting NCT01288651 - Iron Deficiency In Pulmonary Hypertension Phase 4
Recruiting NCT05462574 - Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Completed NCT02565030 - Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
Recruiting NCT01683981 - Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate Phase 0
Completed NCT03069716 - A Mobile Health Intervention in Pulmonary Arterial Hypertension N/A
Completed NCT05767918 - StratosPHere (Non-interventional Study)
Completed NCT00257413 - Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension N/A